NCT01269385View on ClinicalTrials.gov

Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

January 31, 2011

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2015

Conditions
B-cell Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaStage 0 Chronic Lymphocytic LeukemiaStage I Chronic Lymphocytic LeukemiaStage II Chronic Lymphocytic Leukemia
Interventions
BIOLOGICAL

alemtuzumab

Given subcutaneously

BIOLOGICAL

rituximab

Given IV

DRUG

PGG beta-glucan

Given IV

OTHER

flow cytometry

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

GENETIC

DNA analysis

Correlative studies

GENETIC

fluorescence in situ hybridization

Correlative studies

GENETIC

polymerase chain reaction

Correlative studies

GENETIC

polymorphism analysis

Correlative studies

GENETIC

mutation analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT01269385 - Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter